March 10, 2023
Feature
43
3
As the life sciences industry enters this next stage of growth, capitalizing on AI and digital transformation will be key to propelling innovation and ensuring that companies are prepared to tackle the challenges ahead.
March 10, 2023
Features
43
3
While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.
March 10, 2023
Leadership
43
3
The importance of not over-expanding during development, launch.
March 10, 2023
Features
43
3
Global medical affairs teams seek better support to manage relationships with key opinion leaders—and find that balance between patient needs, scientific objectives, and the interest areas of KOLs.
March 10, 2023
Features
43
3
How pharma companies can leverage the lessons learned during the pandemic around key opinion leaders and digital opinion leaders, respectively, to best use new channels of communication. Can both coexist across the healthcare engagement spectrum?
March 10, 2023
Back Page
43
3
The rise of DOLs doesn’t mean pharma should upend KOL approach.
March 10, 2023
Executive Profile
43
3
Chronicling Davidek Herron’s career crossover from playing professional basketball to leading Roche’s digital transformation and scale-up efforts—and the team lessons learned along the way.
March 10, 2023
Finance
43
3
Is stock market outperformance for biotech still in the cards for 2023?
March 10, 2023
Marketing
43
3
How platforms like ChatGPT could transform engagement models.
March 10, 2023
Europe Report
43
3
Region’s diversity plays against efforts to curtail counterfeit drugs.
March 10, 2023
Washington Report
43
3
New candidates are targeting cancer, infectious diseases, and RSV.
March 10, 2023
From the Editor
43
3
While KOLs have been present in healthcare marketing for some time, DOLs are now emerging.
March 10, 2023
Issue PDF
43
3
Click the title above for a link to open the Pharmaceutical Executive March 2023 issue in an interactive PDF format.